HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 8270.0
(6.85%)
KRW 8270.0
(6.85%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.69 Billion KRW | -16.26% |
| 2022 | 7.99 Billion KRW | 73.09% |
| 2021 | 4.61 Billion KRW | -24.16% |
| 2020 | 6.08 Billion KRW | 20.76% |
| 2019 | 5.04 Billion KRW | -3.01% |
| 2018 | 5.19 Billion KRW | 122.72% |
| 2017 | 2.33 Billion KRW | -23.71% |
| 2016 | 3.06 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 952.43 Million KRW | -52.15% |
| 2024 Q1 | 1.99 Billion KRW | 14.98% |
| 2023 FY | 6.69 Billion KRW | -16.26% |
| 2023 Q2 | 1.06 Billion KRW | -23.56% |
| 2023 Q3 | 2.66 Billion KRW | 150.05% |
| 2023 Q4 | 1.73 Billion KRW | -35.04% |
| 2023 Q1 | 1.39 Billion KRW | -46.83% |
| 2022 Q2 | 2.78 Billion KRW | 26.38% |
| 2022 FY | 7.99 Billion KRW | 73.09% |
| 2022 Q4 | 2.62 Billion KRW | -26.94% |
| 2022 Q3 | 3.58 Billion KRW | 28.95% |
| 2022 Q1 | 2.2 Billion KRW | 45.75% |
| 2021 Q4 | 1.51 Billion KRW | -16.43% |
| 2021 Q3 | 1.8 Billion KRW | 0.0% |
| 2021 FY | 4.61 Billion KRW | -24.16% |
| 2020 FY | 6.08 Billion KRW | 20.76% |
| 2019 FY | 5.04 Billion KRW | -3.01% |
| 2018 FY | 5.19 Billion KRW | 122.72% |
| 2017 FY | 2.33 Billion KRW | -23.71% |
| 2016 FY | 3.06 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 211.339% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -46.776% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 88.184% |
| Bioneer Corporation | 199.25 Billion KRW | 96.64% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -202.437% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 83.341% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -359.453% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -215.491% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 97.377% |
| Medy-Tox Inc. | 128.16 Billion KRW | 94.777% |
| Peptron, Inc. | 1.14 Billion KRW | -486.917% |
| Amicogen, Inc. | 51.51 Billion KRW | 87.005% |
| Genexine, Inc. | 387.48 Million KRW | -1627.617% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 62.386% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 78.543% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 96.327% |
| SillaJen, Inc. | 1.45 Billion KRW | -359.536% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 74.817% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 53.584% |
| Genomictree Inc. | -1.03 Billion KRW | 744.55% |
| MedPacto, Inc. | -1.83 Billion KRW | 465.274% |
| D&D Pharmatech | 18.67 Billion KRW | 64.158% |
| EASY BIO,Inc. | 50.88 Billion KRW | 86.845% |
| GI Innovation, Inc. | 1.98 Billion KRW | -236.492% |